Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Use of Topical Metronidazole in the Treatment of Anorectal Crohn's Disease

Author(s):  McElhiney Linda F

Issue:  Sep/Oct 2013 - Volume 17, Number 5
View All Articles in Issue

Page(s):  380-383

Use of Topical Metronidazole in the Treatment of Anorectal Crohn's Disease Page 1
Use of Topical Metronidazole in the Treatment of Anorectal Crohn's Disease Page 2
Use of Topical Metronidazole in the Treatment of Anorectal Crohn's Disease Page 3
Use of Topical Metronidazole in the Treatment of Anorectal Crohn's Disease Page 4

Download in electronic PDF format for $75

Abstract:  Anorectal Crohn’s disease is one of the most problematic and debilitating forms of Crohn’s disease. Crohn’s disease is a type of inflammatory bowel disease that usually affects the intestines but may occur anywhere in the gastrointestinal tract and is frequently refractory to medication, which may ultimately result in proctocolectomy and ileostomy surgeries. It is reported in 3% to 5% of Crohn’s patients and is found in conjunction with colorectal or enteric disease in one-third to one-half of Crohn’s disease patients. This article discusses the use of metronidazole 10% ointment for the treatment of anorectal Crohn’s disease. Since metronidazole is not U.S. Food and Drug Administration approved for treating anorectal Crohn’s disease, and there is no commercially available metronidazole 10% ointment, compounding pharmacists can play a role in providing this dosage form. This article discusses some of the common symptoms of Crohn’s disease and the use of topical metronidazole to treat the disease.

Related Keywords: Linda F. McElhiney, PharmD, RPh, RIACP, FASHP, FACA, metronidazole, formulations, topical preparation, antibiotic, antimicrobial agent, anorectal Crohn's disease, inflammatory bowel disease, anti-inflammatory agents, inflammation, anal fistula plug

Related Categories: FORMULATIONS, GASTROENTEROLOGY, ALLERGY/IMMUNOLOGY/INFLAMMATION, DOSAGE FORMS/DRUG CARRIERS, INFECTIOUS DISEASE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Use of Topical Metronidazole in the Treatment of Anorectal Crohn's Disease
McElhiney Linda F
Sep/Oct 2013
Pg. 380-383

Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
Jul/Aug 2003
Pg. 288-291

The Treatment of Canine Atopic Disease
Davidson Gigi S
May/Jun 2002
Pg. 210-215

Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
Jul/Aug 2004
Pg. 269-274

Treating Canine Hepatic Disease
Davidson Gigi S
May/Jun 2003
Pg. 188-191

Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory
, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
Sep/Oct 2015
Pg. 357-365

Metronidazole 7.5 mg/mL Topical Oil-in-Water Microemulsion
Allen Loyd V Jr
May/Jun 2022
Pg. 238

Case Report: The Quest for a Palatable Compounded Metronidazole (Base) Suspension
McElhiney Linda F
Jan/Feb 2021
Pg. 24-28

A Compendium of Compounding Agents and Formulations, Part 2: Metronidazole, Misoprostol, and Phenytoin
Riepl Mike
Mar/Apr 2022
Pg. 94-98

Case Report: Diabetic Foot Ulcer Infection Treated with Topical Compounded Medications
Agbi Kelechi E
, Carvalho Maria, Phan Ha, Tuma Cristiane
Jan/Feb 2017
Pg. 22-27

Management of Psoriasis with a XemaTop Topical Compounded Formula: A Case Report
Jones Nat
, Carvalho Maria, Branvold-Herr Andrea
May/Jun 2017
Pg. 205-211

Metronidazole 10%, Nifedipine 0.5%, Lidocaine 1.5%, and Diclofenac 3% Ointment
Allen Loyd V Jr
Sep/Oct 2022
Pg. 430

Hydrocortisone 2%, Iodoquinol 1% Metronidazole 10%, and Zinc Oxide 2% in Polyethylene Glycol Ointment
Allen Loyd V Jr
Jan/Feb 2020
Pg. 57

I See Colors: Using Vital Dyes in Diagnosing Ophthalmic Disease
McElhiney Linda F
May/Jun 2012
Pg. 190-195

Sensitization Therapy for Warts
Kuntz Rachael
Jul/Aug 2003
Pg. 266-270

Compounding for Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases
Harrington Amy
, Williams LaVonn
Jul/Aug 2022
Pg. 293-296

Wetting and/or Solubilizing Agents, Featured Excipient:
Allen Loyd V Jr
Jul/Aug 2001
Pg. 310-312

A Compendium of Compounding Agents and Formulations, Part 6: Additional Preparations for Refractory Dermal-wound Healing
Riepl Mike
Nov/Dec 2022
Pg. 480-488

Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration
Kupiec Thomas C
, Ben Michel, Trusley Craig, Trissel Lawrence A
Mar/Apr 2008
Pg. 170-173

Topical Cidofovir for Treatment of Resistant Viral Infections
McElhiney Linda F
Sep/Oct 2006
Pg. 324-328

Return to Top